Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pombiliti and Opfolda in late-onset Pompe disease extension
NCT04138277Phase 3Completed
- Sponsor
- Amicus Therapeutics
- Start
- Dec 2019
- Primary completion
- Dec 2024
- Modality
- Replacement Enzymes
- Countries
- 23
01
Overview
A Phase 3 trial of olipudase alfa in Pompe disease, sponsored by Amicus Therapeutics. Started Dec 2019; status: completed.
02
Drugs
olipudase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NCT04138277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04138277.